Retrospective Observational Study of Acute Subdural Hematoma Treated with Idarucizumab in Japan

Retrospective Observational Study of Acute Subdural Hematoma Treated with Idarucizumab in Japan - Retrospective Observational Study of Acute Subdural Hematoma Treated with Idarucizumab in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047782

Enrollment

Registered

2022-06-01

Start date

2022-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Subdural Hematoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A traumatic acute subdural hematoma was observed while taking dabigatran (anticoagulant), and an elderly person aged 65 years or older who received idarucizumab as a reversal therapy had a head injury.

Exclusion criteria

Exclusion criteria: 1. Multiple trauma cases including trauma to other sites with AIS > 3 2. Cases with coexisting chronic subdural hematoma 3. Cases of cardiopulmonary arrest at the time of delivery

Design outcomes

Primary

Measure	Time frame
Frequency of ischemic complications after reversal therapy	—

Countries

Japan

Contacts

Public ContactEIICHI SUEHIRO

International University of Health and Welfare, School of Medicine Department of Neurosurgery

esuehiro@iuhw.ac.jp0476-35-5600

Outcome results